Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Mission Therapeutics
Biotech
Dimerix buys Mission’s kidney disease prospect in $292M deal
Dimerix is Mission paying $5 million upfront and committing up to $287 million in milestones for the phase 2-ready acute kidney injury asset.
Nick Paul Taylor
Jul 17, 2026 5:00am
Mission changes, shuttering lab to focus on clinical assets
Feb 28, 2025 6:40am
AbbVie picks Alzheimer's, Parkinson's targets for Mission pactÂ
Aug 9, 2021 7:30am
British biotech Mission dubs Pfizer lead investor
Jul 6, 2020 7:35am
AbbVie, Mission Therapeutics join forces on Alzheimer’s, Parkinson’s
Nov 15, 2018 11:11am
EuroBiotech Report—EMA, Vifor, Mission, U.K. and Destiny
Apr 13, 2017 10:40am
